P. Norregaard, F. Moesgaard, F. Bendtsen, and P. Munkholm, Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County: a population-based study from the Danish Crohn colitis database, The American journal of gastroenterology, vol.101, issue.6, pp.1274-82, 2003.

T. Yapp, R. Stenson, G. Thomas, B. Lawrie, G. Williams et al., Crohn??s disease incidence in Cardiff from 1930: an update for 1991-1995, European Journal of Gastroenterology & Hepatology, vol.12, issue.8, pp.907-918, 2000.
DOI : 10.1097/00042737-200012080-00010

G. Rubin, A. Hungin, P. Kelly, and J. Ling, Inflammatory bowel disease: epidemiology and management in an English general practice population, Alimentary Pharmacology and Therapeutics, vol.75, issue.12, pp.1553-1562, 2000.
DOI : 10.1136/gut.46.3.336

C. Loftus, E. Loftus, J. Harmsen, W. Zinsmeister, A. Tremaine et al., Update on the incidence and prevalence of Crohn??s disease and ulcerative colitis in Olmsted County, Minnesota, 1940???2000, Inflammatory Bowel Diseases, vol.13, issue.3, pp.254-61, 1940.
DOI : 10.1002/ibd.20029

R. Fedorak, D. Israel, and J. Blanchard, The epidemiology of inflammatory bowel disease in Canada: a population-based study, The American journal of gastroenterology, vol.101, issue.7, pp.1559-68, 2006.

B. Pinchbeck, J. Kirdeikis, and A. Thomson, Inflammatory bowel disease in northern

C. Bernstein, J. Blanchard, P. Rawsthorne, and A. Wajda, Epidemiology of Crohn's Disease and Ulcerative Colitis in a Central Canadian Province: A Population-based Study, American Journal of Epidemiology, vol.149, issue.10
DOI : 10.1093/oxfordjournals.aje.a009735

E. Dupas, J. Colombel, J. Salomez, J. Cortot, and A. , Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999), Gut, vol.53, issue.6, pp.843-851, 2004.

P. Latour, E. Louis, and J. Belaiche, Incidence of inflammatory bowel disease in the area of

A. Timmer, The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study, European journal of gastroenterology & hepatology, vol.20, issue.9, pp.917-940, 2008.

S. Yang, W. Hong, Y. Min, H. Kim, J. Yoo et al., Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Journal of gastroenterology and hepatology, vol.15, issue.9, pp.1986-19971037, 2000.

A. Sood, V. Midha, N. Sood, A. Bhatia, and G. Avasthi, Incidence and prevalence of ulcerative colitis in Punjab, North India, Gut, vol.52, issue.11, pp.1587-90, 2003.
DOI : 10.1136/gut.52.11.1587

A. Edouard, M. Paillaud, S. Merle, C. Orhan, C. Dagger et al., Incidence of inflammatory bowel disease in the French West Indies (1997-1999), Gastroent??rologie Clinique et Biologique, vol.29, issue.8-9, pp.8-9779, 2005.
DOI : 10.1016/S0399-8320(05)86347-X

K. Thia, E. Loftus, J. Sandborn, W. Yang, and S. , An Update on the Epidemiology of Inflammatory Bowel Disease in Asia, The American Journal of Gastroenterology, vol.40, issue.Suppl 2, pp.3167-82, 2008.
DOI : 10.1111/j.1572-0241.2008.02158.x

J. Cosnes, C. Gower-rousseau, P. Seksik, and A. Cortot, Epidemiology and Natural History of Inflammatory Bowel Diseases, Gastroenterology, vol.140, issue.6, pp.1785-94, 2011.
DOI : 10.1053/j.gastro.2011.01.055

URL : https://hal.archives-ouvertes.fr/hal-00631553

S. Auvin, F. Molinie, C. Gower-rousseau, F. Brazier, M. V. Grandbastien et al., Incidence, Clinical Presentation and Location at Diagnosis of Pediatric Inflammatory Bowel Disease: A Prospective Population-Based Study in Northern France (1988-1999), Journal of Pediatric Gastroenterology and Nutrition, vol.41, issue.1, pp.49-55, 1988.
DOI : 10.1097/01.MPG.0000162479.74277.86

J. Kelsen and R. Baldassano, Inflammatory bowel disease, Inflammatory Bowel Diseases, vol.14, issue.Supplement, pp.9-11, 2008.
DOI : 10.1097/00054725-200810001-00005

E. Langholz, P. Munkholm, P. Krasilnikoff, and V. Binder, Inflammatory Bowel Diseases with Onset in Childhood: Clinical Features, Morbidity, and Mortality in a Regional Cohort, Scandinavian Journal of Gastroenterology, vol.80, issue.2
DOI : 10.3109/00365529709000184

J. Laberenne, J. Salomez, E. Lerebours, D. Turck, A. Cortot et al., The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10-to 19-year-old age bracket, Alimentary pharmacology & therapeutics, vol.33, issue.10, pp.1133-1175, 1988.

R. Gearry, A. Richardson, C. Frampton, J. Collett, M. Burt et al., High incidence of Crohn??s disease in Canterbury, New Zealand: Results of an epidemiologic study, Inflammatory Bowel Diseases, vol.12, issue.10, pp.936-979, 2006.
DOI : 10.1097/01.mib.0000231572.88806.b9

M. Blankenstein, Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD), Gut Fireman Z, vol.39, issue.23, pp.690-697, 1996.

I. Zvidi, R. Hazazi, S. Birkenfeld, and Y. Niv, The Prevalence of Crohn???s Disease in Israel: A 20-Year Survey, Digestive Diseases and Sciences, vol.14, issue.Suppl 170, pp.848-52, 2009.
DOI : 10.1007/s10620-008-0429-1

K. Goh and S. Xiao, Inflammatory bowel disease: A survey of the epidemiology in Asia, Journal of Digestive Diseases, vol.53, issue.Suppl 8
DOI : 10.1111/j.1751-2980.2008.00355.x

B. Calkins, A meta-analysis of the role of smoking in inflammatory bowel disease, Digestive Diseases and Sciences, vol.284, issue.12
DOI : 10.1007/BF01536701

R. Andersson, G. Olaison, C. Tysk, and A. Ekbom, Appendectomy and Protection against Ulcerative Colitis, New England Journal of Medicine, vol.344, issue.11, pp.808-822, 2001.
DOI : 10.1056/NEJM200103153441104

P. Rutgeerts, K. Geboes, G. Vantrappen, J. Beyls, R. Kerremans et al., Predictability of the postoperative course of Crohn's disease, Gastroenterology, vol.99, issue.4, pp.956-63, 1990.
DOI : 10.1016/0016-5085(90)90613-6

G. Olaison, K. Smedh, S. Rhaens, G. Geboes, K. Peeters et al., Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum, Gut Gastroenterology, vol.33114, issue.302, pp.331-5262, 1992.

G. Oberhuber, P. Stangl, H. Vogelsang, E. Schober, F. Herbst et al., Significant association of strictures and internal fistula formation in Crohn's disease, Virchows Archiv, vol.437, issue.3, pp.293-300, 2000.
DOI : 10.1007/s004280000226

J. Colombel, C. Gasche, K. Geboes, D. Jewell, A. Karban et al., Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease, Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

D. Schwartz, J. Pemberton, and W. Sandborn, Diagnosis and Treatment of Perianal Fistulas in Crohn Disease, Annals of Internal Medicine, vol.135, issue.10, pp.906-924, 2001.
DOI : 10.7326/0003-4819-135-10-200111200-00011

P. Munkholm, E. Langholz, M. Davidsen, and V. Binder, Disease Activity Courses in a Regional Cohort of Crohn's Disease Patients, Scandinavian Journal of Gastroenterology, vol.28, issue.7, pp.699-706, 1995.
DOI : 10.1136/bmj.2.6145.1117

A. Schoepfer, Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort, The American journal of gastroenterology, vol.106, issue.1, pp.110-119, 2011.

B. Sands, J. Arsenault, M. Rosen, and M. Alsahli, Clinical course in Crohn's disease: results of a Norwegian population-based ten-year followup study, Clin Gastroenterol Hepatol, vol.5, issue.38, pp.1430-1438, 2007.

A. John, S. Lidofsky, L. Olans, M. Peppercorn, R. Rothstein et al., Risk of early surgery for Crohn's disease: implications for early treatment strategies, The American journal of gastroenterology, vol.98, issue.12, pp.2712-2720, 2003.

J. Cosnes, I. Nion-larmurier, L. Beaugerie, P. Afchain, E. Tiret et al., Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery, Gut, vol.54, issue.2, pp.237-278, 2005.
DOI : 10.1136/gut.2004.045294

J. Salomez, J. Branche, R. Marti, E. Lerebours, A. Cortot et al., Natural history of pediatric Crohn's disease: a population-based cohort study

C. Canavan, K. Abrams, and J. Mayberry, Meta-analysis: mortality in Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.21, issue.7
DOI : 10.1111/j.1365-2036.2007.03276.x

B. Moum, A. Ekbom, M. Vatn, and K. Elgjo, Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time, The American Journal of Gastroenterology, vol.32, issue.170, pp.1564-1573, 1999.
DOI : 10.1111/j.1572-0241.1999.01145.x

M. Joo and R. Odze, Rectal Sparing and Skip Lesions in Ulcerative Colitis: A Comparative Study of Endoscopic and Histologic Findings in Patients Who Underwent Proctocolectomy, The American Journal of Surgical Pathology, vol.34, issue.5, pp.689-96, 2010.
DOI : 10.1097/PAS.0b013e3181db84cd

E. Langholz, P. Munkholm, M. Davidsen, O. Nielsen, and V. Binder, Changes in Extent of Ulcerative Colitis A Study on the Course and Prognostic Factors, Scandinavian Journal of Gastroenterology, vol.88, issue.3, pp.260-266, 1996.
DOI : 10.3109/00365529609004876

E. Langholz, P. Munkholm, M. Davidsen, and V. Binder, Course of ulcerative colitis: Analysis of changes in disease activity over years, Gastroenterology, vol.107, issue.1, pp.3-11, 1994.
DOI : 10.1016/0016-5085(94)90054-X

O. Hoie, F. Wolters, L. Riis, T. Bernklev, G. Aamodt et al., Low Colectomy Rates in Ulcerative Colitis in an Unselected European Cohort Followed for 10 Years, Gastroenterology, vol.132, issue.2, pp.507-522, 2007.
DOI : 10.1053/j.gastro.2006.11.015

R. Xavier and D. Podolsky, Unravelling the pathogenesis of inflammatory bowel disease, Nature, vol.124, issue.7152, pp.427-461, 2007.
DOI : 10.1038/nature06005

K. Papadakis and S. Targan, Tumor necrosis factor: Biology and therapeutic inhibitors, Gastroenterology, vol.119, issue.4
DOI : 10.1053/gast.2000.18160

J. Reimund, C. Wittersheim, S. Dumont, C. Muller, R. Baumann et al., Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease, Journal of Clinical Immunology, vol.40, issue.3, pp.144-50, 1996.
DOI : 10.1007/BF01540912

T. Macdonald, G. Monteleone, and S. Pender, Recent Developments in the Immunology of Inflammatory Bowel Disease, Scandinavian Journal of Immunology, vol.51, issue.1, pp.2-9, 2000.
DOI : 10.1046/j.1365-3083.2000.00658.x

B. Scallon, H. Trinh, M. Nedelman, F. Brennan, M. Feldmann et al., Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins, Cytokine, vol.7, issue.8, pp.759-70, 1995.
DOI : 10.1006/cyto.1995.0091

G. Eissner, W. Kolch, and P. Scheurich, Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system, Cytokine & Growth Factor Reviews, vol.15, issue.5, pp.353-66, 2004.
DOI : 10.1016/j.cytogfr.2004.03.011

W. Sandborn and S. Hanauer, Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety, Inflammatory bowel diseases, vol.5, issue.2, pp.119-152, 1999.

K. Dewoody, T. Schaible, and P. Rutgeerts, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group, The New England journal of medicine, vol.337, issue.15, pp.1029-1064, 1997.

D. Rachmilewitz, D. Wolf, A. Olson, W. Bao, and P. Rutgeerts, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, Lancet, vol.359, issue.60, pp.1541-1550, 2002.

M. Korzenik, J. Lashner, B. Onken, J. Rachmilewitz, D. Rutgeerts et al., Infliximab maintenance therapy for fistulizing Crohn's disease, The New England journal of medicine, vol.350, issue.9, pp.876-85, 2004.

J. Colombel, Infliximab for induction and maintenance therapy for ulcerative colitis, The New England journal of medicine, vol.353, issue.23, pp.2462-76, 2005.

R. Panaccione, D. Wolf, and P. Pollack, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial, Gastroenterology Colombel JF, vol.130, issue.64, pp.323-356, 2006.

S. Schreiber, D. Byczkowski, J. Li, J. Kent, and P. Pollack, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

M. Tighe, M. Lazar, A. Thakkar, and R. , Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, vol.142, issue.2, pp.257-65, 2012.

C. Bernstein, M. Staun, O. Thomsen, and A. Innes, A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease, Gastroenterology, vol.129, issue.3, pp.807-825, 2005.

R. Schreiber and S. , Certolizumab pegol for the treatment of Crohn's disease, Therapeutic Advances in Gastroenterology, vol.4, issue.6, pp.228-266, 2007.
DOI : 10.1177/1756283X11413315

S. Schreiber, M. Khaliq-kareemi, I. Lawrance, O. Thomsen, S. Hanauer et al., Maintenance Therapy with Certolizumab Pegol for Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.239-50, 2007.
DOI : 10.1056/NEJMoa062897

M. Lemann and J. Colombel, The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies, Alimentary pharmacology & therapeutics, vol.31, issue.1, pp.92-101, 2010.

T. Johnson, N. Diehl, and A. Zinsmeister, Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterology, vol.121, issue.72, pp.1088-94, 2001.

P. Infliximab, azathioprine, or combination therapy for Crohn's disease, The New England journal of medicine, vol.362, issue.15, pp.1383-95, 2010.

J. Colombel and L. Egan, Risk factors for opportunistic infections in patients with inflammatory bowel disease, Gastroenterology, vol.134, issue.4, pp.929-965, 2008.

A. Mackey, L. Green, L. Liang, P. Dinndorf, and M. Avigan, Hepatosplenic T Cell Lymphoma Associated With Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease, Journal of Pediatric Gastroenterology and Nutrition, vol.44, issue.2, pp.265-272, 2007.
DOI : 10.1097/MPG.0b013e31802f6424

K. Steen, S. Vermeire, and P. Rutgeerts, Long-term outcome of treatment with infliximab, p.614

D. Rachmilewitz, D. Wolf, A. Olson, W. Bao, S. Hanauer et al., Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF, Gastroenterology Inflammatory bowel diseases, vol.12616, issue.7911, pp.402-131898, 2004.

A. Pink, A. Fonia, M. Allen, C. Smith, and J. Barker, Population pharmacokinetics of infliximab in patients with ankylosing spondylitis Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study, Journal of clinical pharmacology The British journal of dermatology, vol.48162, issue.814, pp.681-95780, 2008.

X. Bossuyt, P. Rutgeerts, R. Villela, M. Silverberg, and G. Greenberg, Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease, Gastroenterology, vol.125, issue.1, pp.32-41, 2003.

B. Pariente, P. De-chambrun, G. Krzysiek, R. Desroches, M. Louis et al., Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.18, issue.7, pp.1199-206, 2012.
DOI : 10.1002/ibd.21839

L. Peyrin-biroulet, P. Desreumaux, W. Sandborn, and J. Colombel, Crohn's disease: beyond antagonists of tumour necrosis factor, The Lancet, vol.372, issue.9632, pp.67-81, 2008.
DOI : 10.1016/S0140-6736(08)60995-2

E. Keystone, The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis and rheumatism, vol.46, issue.6, pp.1451-1460, 2002.

P. Mulani, U. Kopylov, G. Mantzaris, K. Katsanos, C. Reenaers et al., Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab, Inflammatory bowel diseases Alimentary pharmacology & therapeutics, vol.1733, issue.893, pp.141-51349, 2011.

G. , L. J. Rosenfeld, M. Kent, J. Pollack, and P. , Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial, Annals of internal medicine, vol.146, issue.12, pp.829-867, 2007.

K. Claes, T. Coopman, V. Schuerbeek, N. Van-assche, G. Vermeire et al., Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease, Gastroenterology, vol.137, issue.5, pp.1628-1668, 2009.

E. Humblet, V. Casteele, N. Gils, A. Rutgeerts, and P. , Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial, Gut, vol.61, issue.2, pp.229-263, 2012.

D. Ternant, H. Watier, G. Paintaud, and P. Rutgeerts, Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial, Gastroenterology, vol.134, issue.7, pp.1861-1869, 2008.

S. Vermeire, M. Noman, G. Van-assche, F. Baert, D. Haens et al., Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease, Gut, vol.56, issue.9, pp.1226-1257, 2007.
DOI : 10.1136/gut.2006.099978

J. Cosnes, F. Carbonnel, L. Beaugerie, L. Quintrec, Y. Gendre et al., Effects of cigarette smoking on the long-term course of Crohn's disease, 98. Gaertner WB, pp.424-455, 1996.
DOI : 10.1053/gast.1996.v110.pm8566589

M. Spencer, Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Diseases of the colon and rectum, pp.1754-60, 2007.

B. Flourie, X. Hebuterne, M. Bigard, and L. Peyrin-biroulet, A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization, The American journal of gastroenterology, vol.105, issue.12, pp.2617-2642, 2010.

D. Haens, G. Baert, F. Van-assche, G. Caenepeel, P. Vergauwe et al., Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, The Lancet, vol.371, issue.9613, pp.660-667, 2008.
DOI : 10.1016/S0140-6736(08)60304-9

S. Plevy, Infliximab prevents Crohn's disease recurrence after ileal resection

M. Chaparro, J. Panes, V. Garcia, M. Manosa, M. Esteve et al., Long-term Durability of Infliximab Treatment in Crohn??s Disease and Efficacy of Dose ???Escalation??? in Patients Losing Response, Journal of Clinical Gastroenterology, vol.45, issue.2, pp.113-121, 2011.
DOI : 10.1097/MCG.0b013e3181ebaef9

R. Baldassano, Induction and maintenance infliximab therapy for the treatment of moderateto-severe Crohn's disease in children, Gastroenterology, vol.132, issue.3, pp.863-73, 2007.

K. Lin, F. Velayos, E. Fisher, and J. Terdiman, Durability of Infliximab Dose Intensification in Crohn???s Disease, Digestive Diseases and Sciences, vol.7, issue.4, pp.1013-1022, 2011.
DOI : 10.1007/s10620-011-1969-3

B. Casis, A. Roman, A. Algaba, J. Mate, and J. Gisbert, Intensification of infliximab therapy in Crohn's disease: efficacy and safety, Journal of Crohn's & colitis, vol.6, issue.1, pp.62-69, 2012.

G. Mocci, M. Marzo, A. Papa, A. Armuzzi, and L. Guidi, Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease, Journal of Crohn's and Colitis, vol.7, issue.10, 2013.
DOI : 10.1016/j.crohns.2013.01.009

D. Laharie, A. Bourreille, J. Branche, M. Allez, Y. Bouhnik et al., Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial, The Lancet, vol.380, issue.9857, pp.1909-1924, 2012.
DOI : 10.1016/S0140-6736(12)61084-8

URL : https://hal.archives-ouvertes.fr/hal-00742308